Zealand Pharma and OTR to develop metabolic disease therapeutics [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
The multi-programme partnership leverages Zealand Pharma's experience in obesity and metabolic health alongside OTR Therapeutics' research and development (R&D) platform to address the needs of people with metabolic diseases. OTR Therapeutics will use its discovery platform to carry out research and preclinical development activities. Zealand Pharma will take on the responsibility for clinical development, regulatory submissions and global commercialisation. Zealand Pharma chief scientific officer Utpal Singh stated: "This partnership is an early testament - with more to follow - to the execution of our updated strategy to further strengthen and evolve our platform, broadening treatment options for people living with overweight, obesity and other metabolic diseases. “We are confident the partnership with OTR Therapeutics will be highly productive in achieving our shared goal of expanding treatment options for people living with metabolic diseases.” OTR Therapeutics will obt
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- FDA proposes allowing sunscreen ingredient already used in Europe and Asia [MSNBC.com]MSNBC.com
- Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry's broadest in vitro diagnostic menu [Yahoo! Finance]Yahoo! Finance
- Genentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer [Yahoo! Finance]Yahoo! Finance
- Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast CancerBusiness Wire
- Roche (OTCMKTS:RHHBY) had its "buy" rating reaffirmed by analysts at HSBC Holdings plc.MarketBeat